Seegene

Seegene EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of Seegene (096530.KQ) as of Oct 31, 2026 is 2.80 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was -3.69 % — a change of -175.83% (higher).

EBIT/Assets

2.80 %

YoY

-175.83%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of Seegene is 2025 2.80 % . Operating Income to Assets Ratio (EBIT/Assets) of Seegene was 2024 -3.69 % . It decreases by -175.83% higher compared to the previous year.

The Seegene EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2018
6.31 KRW
Jan 1, 2019
11.86 KRW
Jan 1, 2020
61.72 KRW
Jan 1, 2021
44.75 KRW
Jan 1, 2022
14.11 KRW
Jan 1, 2023
-2.36 KRW
Jan 1, 2024
-3.69 KRW
Jan 1, 2025
2.80 KRW
The Seegene EBIT/Assets history
YEAREBIT/AssetsYoY
2.80 %-175.83%
-3.69 %+56.13%
-2.36 %-116.73%
14.11 %-68.46%
44.75 %-27.49%
61.72 %+420.20%
11.86 %+88.05%
6.31 %+106.76%
3.05 %-34.80%
4.68 %+15.27%
4.06 %-49.44%
8.03 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Seegene Stock analysis

What does Seegene do? Seegene, Inc. generates revenue through the manufacturing and distribution of molecular diagnostics and reagents. The company offers infectious pathogens inspection products, including those for allergic respiratory pathogens, sexually transmitted diseases, and human papilloma virus (HPV), alongside drug resistance, single nucleotide polymorphisms (SNP), and somatic mutation cancer inspection products. It also provides automatic real-time detection instruments under the brand names Seeplex, Anyplex, and Magicplex. The firm serves both domestic and overseas markets with these products. The primary customers for Seegene's products are healthcare providers and laboratories requiring diagnostic solutions. The company's product portfolio targets specific medical needs such as infectious disease testing and cancer diagnostics. Its brands Seeplex, Anyplex, and Magicplex are used across various diagnostic applications, including respiratory and sexually transmitted disease testing. The firm's focus on molecular diagnostics positions it within the healthcare sector for specialized testing services. Seegene's revenue streams are derived from the sale of its branded diagnostic products and instruments. The company's domestic and overseas market distribution strategy supports its business model, with Seeplex, Anyplex, and Magicplex serving as key product lines. The firm's offerings cater to the growing demand for accurate and efficient molecular diagnostic solutions in healthcare settings. Seegene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Seegene stock

Operating Income to Assets Ratio (EBIT/Assets) of Seegene is 2.80 % in 2025.

Operating Income to Assets Ratio (EBIT/Assets) of Seegene changed from -3.69 % to 2.80 %, representing a -175.83% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) Seegene since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s Seegene with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Seegene

All Key Metrics — Seegene